Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Animals
Antineoplastic Agents
/ administration & dosage
Apoptosis
/ drug effects
Bone Neoplasms
/ drug therapy
Caffeine
/ administration & dosage
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Central Nervous System Stimulants
/ administration & dosage
Cisplatin
/ administration & dosage
Citrates
/ administration & dosage
Drug Synergism
Drug Therapy, Combination
Female
Fibrosarcoma
/ drug therapy
Humans
Membrane Potential, Mitochondrial
/ drug effects
Mice
Mice, Nude
Osteosarcoma
/ drug therapy
Treatment Outcome
Tumor Burden
Xenograft Model Antitumor Assays
Caffeine citrate
Cancer
Chemotherapy
Fibrosarcoma
Osteosarcoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
05
02
2019
accepted:
28
06
2019
entrez:
17
7
2019
pubmed:
17
7
2019
medline:
18
12
2019
Statut:
epublish
Résumé
While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. Caffeine can induce apoptosis, delays in cell cycle progression and can enhance the cytocidal effects of anti-cancer agents. Citrate has been reported to enhance the cytocidal effect of cisplatin in gastric cancer in vitro. However its effect in sarcoma cells had not been reported. This study was designed to evaluate whether the addition of caffeine, citrate, or caffeine citrate to cisplatin improved its cytocidal effect (cell survival, proliferation, and apoptosis) on human osteosarcoma (HOS), human fibrosarcoma (HT1080) and murine osteosarcoma (LM8) cell lines. We also tested the various combinations in a mouse heterotopic transplantation model in vivo. In cell survival assay, combination index (CI) of caffeine citrate was calculated as a combination of anhydrous caffeine and citric acid, and the synergy was evaluated (CI < 1.0). In all cell lines, cisplatin combined with caffeine citrate significantly reinforced the anticancer effect compared with cisplatin alone, combination of cisplatin and anhydrous caffeine, and combination of cisplatin and citric acid. Moreover, CI was < 1.0 in all conditions. The anticancer agent reinforcement effect of caffeine citrate was synergy of anhydrous caffeine and citric acid. In cell proliferation and cell cycle assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in inducing G0/G1 cell-cycle arrest with subsequent suppressed cell proliferation. In mitochondrial depolarization and caspase 3/7 activity assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in apoptosis associated with decreased mitochondrial membrane potential. In vivo, three different drug concentrations were tested, and cisplatin combined with caffeine citrate was found to have the strongest antitumor effect. This is the first report demonstrating that caffeine citrate has a significantly greater potentiating effect on cisplatin than adding either caffeine or citric acid. The combination of cisplatin with caffeine citrate is a novel treatment that might hold promise for improving the outcome of osteosarcoma and fibrosarcoma, which up till now has generally not responded well to chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. Caffeine can induce apoptosis, delays in cell cycle progression and can enhance the cytocidal effects of anti-cancer agents. Citrate has been reported to enhance the cytocidal effect of cisplatin in gastric cancer in vitro. However its effect in sarcoma cells had not been reported.
METHODS
METHODS
This study was designed to evaluate whether the addition of caffeine, citrate, or caffeine citrate to cisplatin improved its cytocidal effect (cell survival, proliferation, and apoptosis) on human osteosarcoma (HOS), human fibrosarcoma (HT1080) and murine osteosarcoma (LM8) cell lines. We also tested the various combinations in a mouse heterotopic transplantation model in vivo. In cell survival assay, combination index (CI) of caffeine citrate was calculated as a combination of anhydrous caffeine and citric acid, and the synergy was evaluated (CI < 1.0).
RESULTS
RESULTS
In all cell lines, cisplatin combined with caffeine citrate significantly reinforced the anticancer effect compared with cisplatin alone, combination of cisplatin and anhydrous caffeine, and combination of cisplatin and citric acid. Moreover, CI was < 1.0 in all conditions. The anticancer agent reinforcement effect of caffeine citrate was synergy of anhydrous caffeine and citric acid. In cell proliferation and cell cycle assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in inducing G0/G1 cell-cycle arrest with subsequent suppressed cell proliferation. In mitochondrial depolarization and caspase 3/7 activity assay revealed that caffeine citrate had most strong effect as a combination drug than caffeine and citric acid in apoptosis associated with decreased mitochondrial membrane potential. In vivo, three different drug concentrations were tested, and cisplatin combined with caffeine citrate was found to have the strongest antitumor effect.
CONCLUSIONS
CONCLUSIONS
This is the first report demonstrating that caffeine citrate has a significantly greater potentiating effect on cisplatin than adding either caffeine or citric acid. The combination of cisplatin with caffeine citrate is a novel treatment that might hold promise for improving the outcome of osteosarcoma and fibrosarcoma, which up till now has generally not responded well to chemotherapy.
Identifiants
pubmed: 31307409
doi: 10.1186/s12885-019-5891-y
pii: 10.1186/s12885-019-5891-y
pmc: PMC6631922
doi:
Substances chimiques
Antineoplastic Agents
0
Central Nervous System Stimulants
0
Citrates
0
Caffeine
3G6A5W338E
Cisplatin
Q20Q21Q62J
caffeine citrate
U26EO4675Q
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
689Références
Cancer Res. 1999 Sep 1;59(17):4375-82
pubmed: 10485486
J Bone Joint Surg Br. 2002 Jan;84(1):88-92
pubmed: 11837839
Cancer Res. 2003 Jan 1;63(1):80-5
pubmed: 12517781
Cancer Res. 2003 Aug 1;63(15):4396-401
pubmed: 12907610
J Cancer Res Clin Oncol. 1992;118(8):567-9
pubmed: 1517277
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
J Bone Joint Surg Am. 2004 Dec;86(12):2686-93
pubmed: 15590854
Radiat Res. 1978 Nov;76(2):292-307
pubmed: 156382
Genes Dev. 2005 Jun 1;19(11):1294-305
pubmed: 15901672
IARC Monogr Eval Carcinog Risks Hum. 1991;51:1-513
pubmed: 1674554
J Bone Joint Surg Am. 2007 Jun;89(6):1399-407
pubmed: 17545444
Skin Pharmacol. 1991;4(4):286-90
pubmed: 1789989
Curr Mol Med. 2008 Mar;8(2):138-47
pubmed: 18336294
Int J Cancer. 2009 Jul 1;125(1):229-34
pubmed: 19330840
Anticancer Res. 2009 Apr;29(4):1249-54
pubmed: 19414371
Expert Opin Drug Deliv. 2009 Dec;6(12):1311-21
pubmed: 19761419
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Carcinogenesis. 2010 Jun;31(6):984-93
pubmed: 20142415
Pediatr Radiol. 2011 Feb;41(2):227-36
pubmed: 20814672
Int J Oncol. 2011 Aug;39(2):465-72
pubmed: 21617855
Cell. 2011 Aug 19;146(4):607-20
pubmed: 21854985
Biol Pharm Bull. 2012;35(3):400-7
pubmed: 22382328
Anticancer Res. 2012 Sep;32(9):3643-9
pubmed: 22993301
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
J Cell Biochem. 2013 Nov;114(11):2454-60
pubmed: 23696238
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336
Oncol Res Treat. 2014;37(6):355-62
pubmed: 24903768
J Clin Oncol. 1989 Sep;7(9):1208-16
pubmed: 2504890
Exp Hematol Oncol. 2015 Feb 11;4:5
pubmed: 25937999
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
Life Sci. 1989;45(11):947-61
pubmed: 2677570
J Clin Oncol. 2016 Jul 1;34(19):2294-302
pubmed: 27185843
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Anticancer Res. 2017 Mar;37(3):1005-1011
pubmed: 28314258
J Pharmacol Exp Ther. 1988 Nov;247(2):603-8
pubmed: 3183956
Proc Natl Acad Sci U S A. 1982 May;79(9):2942-6
pubmed: 6953438
J Clin Oncol. 1995 Jul;13(7):1537-45
pubmed: 7602342
J Clin Oncol. 1993 Jul;11(7):1269-75
pubmed: 8315424
J Clin Oncol. 1993 Jul;11(7):1276-85
pubmed: 8315425
Anticancer Res. 1998 Jan-Feb;18(1B):657-66
pubmed: 9584049
Clin Orthop Relat Res. 1999 Jan;(358):27-35
pubmed: 9973973